Bruna Desjardins

Various consulting missions to help organizations define and execute successful go-to-market strategies, optimize brand positioning, and empower field teams to deliver sustainable performance.

Recruitment & Management of a Diverse Commercial Team (10 people): Led a cross-functional team, including brand managers, a sales director, and hospital sales reps, fostering collaboration and strategic alignment across all functions. Local Commercial Strategy for 3 Major Products: Defined and implemented tailored strategies with a focus on omnichannel and AI-driven approaches, tackling unique challenges in each therapeutic area: Koselugo (Plexiform Neurofibromas): Successful launch strategy with clear identification of patient and HCP journey, raising awareness and providing specific training for side effect management. Outcome: +250% patient growth after 1 year following an early access program (EAP). Strensiq (Hypophosphatasia): Revitalized communication positioning Strensiq earlier in the patient pathway, resulting in a +2 patient increase within 3 months. Kanuma (Lysosomal Acid Lipase Deficiency): Tackled access barriers to unlock treatment availability for patients. Member of the Pre-LBT (Launch Business Team) for the Metabolics Portfolio: Contributed strategically to the pre-launch planning of CAEL-101 in AL-amyloidosis, including launch strategy, resource forecasting, and timeline management. Strong Collaboration with Commercial Leadership & Global Teams: Worked closely with both local and global teams to ensure the alignment of commercial strategies, optimizing performance and outcomes. OPEX & Financial Forecasting: Managed operational expenses, tracked performance, and defined long-term forecasts to drive profitability and operational efficiency. CODIR Interim Member: Stepped into a leadership role within the CODIR committee during a transitional period, ensuring continuity in critical commercial decision-making processes.

Creation & Leadership of a Rare Diseases Commercial Team: Built and led a high-performing team dedicated to rare diseases, including sales and marketing professionals. Fostered a culture of collaboration, innovation, and excellence to drive performance across the portfolio. Sales Strategy & Objective Definition: Defined clear sales targets and objectives, monitored performance, and implemented corrective actions where necessary to meet targets. Conducted deep sales analysis to identify growth opportunities and optimize sales performance. National Strategy Development for Ledaga: Led the design and execution of the national strategy to optimize the growth of Ledaga in the onco-dermatology space. Focused on market positioning, stakeholder engagement, and promotional tactics to maximize product adoption. Defense Strategy for Metabolic Portfolio: Developed and implemented strategies to defend against generics entry and preserve Carbaglu market share. This included market analysis, competitor tracking, and forecast development to inform strategic decision-making. Financial Performance: Achieved a turnover of €20M in 2021 (+3% vs PY), demonstrating strong revenue growth and efficient portfolio management. Successfully navigated challenges within the competitive landscape while driving the business forward. Market Analysis & Forecasting: Led market analysis initiatives, identifying trends, challenges, and growth opportunities. Developed accurate forecasts that informed strategic decision-making and ensured alignment with long-term goals.

Local Multichannel Strategy: Defined and executed a tailored multichannel strategy for the French market, implementing innovative media like Patient University, interactive web conferences, and masterclasses. Access Strategy & Launch Extensions: Led access strategies for product launch extensions, including new packaging, dosages, and pediatric indications, ensuring smooth market entry. Sales & Patient Forecasting: Managed sales and patient forecasting, set clear goals, and tracked performance to achieve business objectives. Cross-Functional Collaboration: Worked closely with global teams and affiliates, sharing market insights and training on Short Bowel Syndrome for the successful launch of Revestive internationally. KOL & Field Engagement: Developed strong partnerships with Key Opinion Leaders and conducted double field visits to drive product awareness and adoption. Competitive Intelligence: Conducted market analysis and competitive intelligence to inform strategic decisions. Awards: Product recognized with the Prix Galien and CEO Award for its market impact.

Promotional Tools Development: Designed promotional materials for practitioners and patients. Congress Support: Created content and new posts for congress presentations to enhance brand visibility. Competitive Intelligence: Conducted market research and competitive analysis to inform strategic planning.

Antihypertensive Compound Synthesis: Synthesized new compounds targeting pulmonary hypertension, contributing to the development of innovative treatments.